Growth

Teriparatide.

Available Variants

10 mg

View lab reports Quality process

Research area: Growth

🛡️

For research purposes only. Not intended for use in humans or animals.

GH-axis research

About Teriparatide

Teriparatide is among the peptides researched in the context of the growth hormone (GH) axis. Intermittent (daily) dosing activates PTH1 receptors on osteoblasts, producing a net anabolic (bone-building) effect, in contrast to the catabolic effect of continuously elevated endogenous PTH.

Research Application

The reference anabolic osteoporosis agent in research, used to study bone-formation pathways and as a comparator for newer anabolic bone agents.

Important to know

Claims circulating online are often not backed by valid clinical data. Treat all information as a starting point for your own scientific research, not as usage guidance.

Content 10 mg

Form Lyophilized powder

Category Growth

Purity & Identity see lab reports →

Sequence / Structure Recombinant human parathyroid hormone fragment PTH(1-34), the biologically active N-terminal 34-amino-acid portion of full-length parathyroid hormone.

Regulatory Status FDA-approved (Forteo, Eli Lilly) since November 2002 for osteoporosis; also approved in Germany/EU. The boxed warning for osteosarcoma risk and 2-year treatment limit were removed by the FDA in November 2020.

Sequence and regulatory status data are based on publicly available sources and refer to the compound in general, not to a specific product.

Research Overview

Numerous preclinical and some clinical studies exist on the GH axis, with evidentiary strength varying by substance.

Neer RM, et al. N Engl J Med. 2001;344(19):1434–1441. PMID 11346808

References without a PMID can be located via the respective publisher. This overview does not claim to be exhaustive.

Similar Peptides

Regeneration B7-33 View → Growth IGF-1 LR3 View → Growth HGH View →

Question about Teriparatide?

We reply personally – via email or Telegram.

✉️ Email ✈️ Telegram

← Back to overview